aspirin has been researched along with Fetal Death in 119 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Fetal Death: Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2." | 9.19 | Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014) |
| "Aspirin desensitization may be a safe alternative even during pregnancy if carefully monitored and permit patients with APS to receive treatment with ASA." | 9.12 | Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. ( Alijotas-Reig, J; Cisteró-Bahíma, A; San Miguel-Moncín, M, 2006) |
| "The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia)." | 9.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| "The effect of administration of a prophylactic dose of controlled-release aspirin on the prevention of pre-eclampsia was investigated in a randomized placebo-controlled trial conducted at the Queen Elizabeth Hospital in Barbados in 1992-94." | 9.08 | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 9.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 8.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 8.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 8.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "Recent surveys of prenatal drug consumption indicate that aspirin is the most frequently consumed drug in pregnancy." | 8.75 | Aspirin in pregnancy: maternal and fetal effects. ( Corby, DG, 1978) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 8.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "When platelet function was assessed with COX-specific tests that measure the antiplatelet effects of low-dose aspirin and aspirin adherence is accurately accounted for aspirin non-responsiveness was not identified in pregnant women at high-risk of pre-eclampsia." | 7.88 | Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. ( Alfirevic, A; Alfirevic, Z; Jorgensen, A; Navaratnam, K, 2018) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Descriptions of salicylate poisoning during pregnancy are rare and unique features of perinatal physiology predict an increased sensitivity of the fetus to aspirin poisoning." | 7.70 | Aspirin poisoning during pregnancy: increased fetal sensitivity. ( Palatnick, W; Tenenbein, M, 1998) |
| "Despite an improvement in outcomes in the aspirin treated pregnancy, histologic evidence of uterine vascular pathology persisted in the majority of women with a prior complicated pregnancy demonstrating similar placental lesions." | 7.69 | Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. ( Campbell, WA; Cusick, W; Ernst, L; Rodis, JF; Salafia, CM; Vintzileos, AM, 1995) |
| " Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established." | 7.68 | [A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992) |
| "A 27-year-old woman with anti-phospholipid antibody syndrome, whose first pregnancy had ended in intrauterine fetal death, was treated with prednisolone 0." | 7.68 | [Fetal survival after the corticosteroid and low-dose aspirin regimen in a case of anti-phospholipid antibody syndrome]. ( Maruyama, I; Maruyama, Y; Okadome, T; Osame, M; Shimmyozu, K; Tara, M, 1990) |
| " there was no evidence that aspirin taken in pregnancy is a cause of stillbirth, neonatal death, or reduced birth-weight." | 7.65 | Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy. ( Heinonen, OP; Kaufman, DW; Monson, RR; Shapiro, S; Siskind, V; Slone, D, 1976) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 6.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "Its use during pregnancy is considered as safe, provided the daily doses do not exceed 100mg." | 6.55 | [Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017) |
| "After treatment the pregnancy wastage rate was 55% and 25% in the 2 groups respectively." | 5.28 | Pregnancy loss with phospholipid antibodies: improved outcome with aspirin containing treatment. ( Cameron, K; Gatenby, PA; Shearman, RP, 1989) |
| "To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2." | 5.19 | Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014) |
| "Aspirin desensitization may be a safe alternative even during pregnancy if carefully monitored and permit patients with APS to receive treatment with ASA." | 5.12 | Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. ( Alijotas-Reig, J; Cisteró-Bahíma, A; San Miguel-Moncín, M, 2006) |
| "The effect of administration of a prophylactic dose of controlled-release aspirin on the prevention of pre-eclampsia was investigated in a randomized placebo-controlled trial conducted at the Queen Elizabeth Hospital in Barbados in 1992-94." | 5.08 | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. ( Ayers, S; Collins, R; Cruickshank, JK; Duley, L; Farrell, B; Gay, MP; Grant, A; Griffiths, J; Hennis, A; Rotchell, YE; Stewart, A, 1998) |
| "The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia)." | 5.08 | ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. ( , 1996) |
| "A multicentric randomized double-blind trial was realized in order to determine whether a treatment with a low-dose aspirin (150 mg/day) with or without dipyridamole (225 mg/day) was able to prevent the perinatal consequences of pre-eclampsia." | 5.07 | Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group. ( Sureau, C, 1991) |
| "The use of aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS have a successful pregnancy outcome." | 4.95 | Current insights in obstetric antiphospholipid syndrome. ( Radin, M; Schreiber, K; Sciascia, S, 2017) |
| "Databases were searched for keywords related to aspirin and pregnancy." | 4.89 | Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. ( Bujold, E; Demers, S; Nicolaides, KH; Roberge, S; Villa, P, 2013) |
| " Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin." | 4.85 | [The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009) |
| "Antiplatelet agents, largely low-dose aspirin, have moderate benefits when used for prevention of pre-eclampsia and its consequences." | 4.84 | Antiplatelet agents for preventing pre-eclampsia and its complications. ( Duley, L; Henderson-Smart, DJ; King, JF; Meher, S, 2007) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 4.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| "Although intra-uterine fetal death is considered at high risk of recurrence in case of antiphospholipid syndrome (APS), a uniform management protocol including aspirin and heparin and close obstetrical follow-up led to a favorable outcome in most cases." | 4.82 | Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy. ( Bats, AS; Carbonne, B; Cynober, E; Gonzales, M; Lejeune, V; Milliez, J; Safar, E, 2004) |
| "Antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia." | 4.81 | Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. ( Duley, L; Henderson-Smart, D; King, J; Knight, M, 2001) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 4.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 4.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "Recent surveys of prenatal drug consumption indicate that aspirin is the most frequently consumed drug in pregnancy." | 4.75 | Aspirin in pregnancy: maternal and fetal effects. ( Corby, DG, 1978) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 4.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "When platelet function was assessed with COX-specific tests that measure the antiplatelet effects of low-dose aspirin and aspirin adherence is accurately accounted for aspirin non-responsiveness was not identified in pregnant women at high-risk of pre-eclampsia." | 3.88 | Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. ( Alfirevic, A; Alfirevic, Z; Jorgensen, A; Navaratnam, K, 2018) |
| "All consecutive women between 24 and 36weeks gestation with an indication for aspirin use during pregnancy were invited for this study." | 3.83 | Aspirin adherence during high-risk pregnancies, a questionnaire study. ( Abheiden, CN; de Boer, MA; de Vries, JI; Fuijkschot, WW; Thijs, A; van Reuler, AV, 2016) |
| "To identify patients at very high risk for adverse pregnancy outcome (APO) at the 20- to 23-week scan and to assess the effectiveness of Aspirin (ASS) and low molecular weight heparin (LMWH) starting after this examination." | 3.79 | Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects. ( Becker, R; Bittner, U; Fangerau, H; Keller, T; Kiesewetter, H, 2013) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Descriptions of salicylate poisoning during pregnancy are rare and unique features of perinatal physiology predict an increased sensitivity of the fetus to aspirin poisoning." | 3.70 | Aspirin poisoning during pregnancy: increased fetal sensitivity. ( Palatnick, W; Tenenbein, M, 1998) |
| "To our knowledge, this is the first time that a combination of aspirin and glyceryl trinitrate (GTN) has been used in the prophylaxis of preeclampsia and fetal growth retardation, and their use associated with not only Doppler screening of the uterine arteries but also regular Doppler follow-up of the fetal arterial and venous circulation." | 3.70 | A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth. ( Black, RS; Campbell, S; Lees, CC; Oyelese, KO, 1998) |
| " In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly." | 3.69 | [Recurrent fetal death and antiphospholipid antibody syndrome. A case report]. ( Bustos López, HH; Hernández Andrade, E; Ramírez Peredo, J; Rojas-Poceros, G, 1997) |
| "Despite an improvement in outcomes in the aspirin treated pregnancy, histologic evidence of uterine vascular pathology persisted in the majority of women with a prior complicated pregnancy demonstrating similar placental lesions." | 3.69 | Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. ( Campbell, WA; Cusick, W; Ernst, L; Rodis, JF; Salafia, CM; Vintzileos, AM, 1995) |
| " Many studies have suggested that treatment with low-dose aspirin and steroids is effective in preventing pregnancy loss or pre-eclampsia, but the mechanism has not been established." | 3.68 | [A trial of low-dose aspirin therapy in high-risk pregnancy]. ( Mochizuki, M; Morikawa, H; Ohashi, M; Takashima, M; Yamasaki, M, 1992) |
| "A 27-year-old woman with anti-phospholipid antibody syndrome, whose first pregnancy had ended in intrauterine fetal death, was treated with prednisolone 0." | 3.68 | [Fetal survival after the corticosteroid and low-dose aspirin regimen in a case of anti-phospholipid antibody syndrome]. ( Maruyama, I; Maruyama, Y; Okadome, T; Osame, M; Shimmyozu, K; Tara, M, 1990) |
| " During their next pregnancy, the patients were treated with 40 to 50 mg of prednisone per day and 81 mg of aspirin per day." | 3.67 | Obstetric complications associated with the lupus anticoagulant. ( Branch, DW; Hershgold, E; Kochenour, NK; Scott, JR, 1985) |
| " there was no evidence that aspirin taken in pregnancy is a cause of stillbirth, neonatal death, or reduced birth-weight." | 3.65 | Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy. ( Heinonen, OP; Kaufman, DW; Monson, RR; Shapiro, S; Siskind, V; Slone, D, 1976) |
| "Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery." | 2.67 | CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. ( , 1994) |
| "Its use during pregnancy is considered as safe, provided the daily doses do not exceed 100mg." | 2.55 | [Aspirin: Indications and use during pregnancy]. ( Belhomme, N; Doudnikoff, C; Henriot, B; Isly, H; Jego, P; Polard, E, 2017) |
| "Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit." | 2.47 | Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011) |
| "Antiphospholipid syndrome is one of the few treatable causes of pregnancy loss, and successful pregnancy rates of 70% or more can be achieved with appropriate treatment." | 2.44 | [Pregnancy and antiphospholipid antibodies]. ( Goffinet, F; Le Guern, V, 2008) |
| "Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition." | 2.42 | [Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003) |
| "Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well." | 2.42 | [Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003) |
| "If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved." | 2.41 | A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| " The teratogenic potential of a drug is related to dosage and time of administration." | 2.36 | Analgesics during pregnancy. ( Niederhoff, H; Zahradnik, HP, 1983) |
| "Eleven women with recurrent miscarriage (14." | 1.42 | Clinical characteristics of pregnancies with a history of recurrent miscarriage at a Japanese perinatal center. ( Nakanishi, K; Suzuki, S; Terada, K, 2015) |
| "Last, we show that the recurrence rate of an adverse pregnancy outcome persisted at 30% despite treatment intervention." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| "No patients with preeclampsia or other severe complications of pregnancy were observed in the normalised group." | 1.31 | Late normalisation of uterine artery velocimetry in high risk pregnancy. ( Danti, L; Frusca, T; Scalvi, L; Soregaroli, M; Valcamonico, A, 2001) |
| "Management of ET in pregnancy is still very much individualized." | 1.31 | Four pregnancies in two patients with essential thrombocythaemia--a case report. ( Devendra, K; Koh, LP; Tien, SL, 2002) |
| "Increased risk for aplasia cutis congenita should be considered when elevated maternal and amniotic fluid alpha-fetoprotein and a distinct electrophoretic band of acetylcholinesterase are found." | 1.29 | Aplasia cutis congenita, elevated alpha-fetoprotein, and a distinct amniotic fluid acetylcholinesterase electrophoretic band. ( Cohen, RN; Dror, Y; Gelman-Kohan, Z; Hagai, Z; Juster-Reicher, A; Mogilner, B, 1994) |
| "The patient had experienced hepatic infarction during her first pregnancy and had repeated hepatic infarction during her third pregnancy." | 1.29 | Hepatic infarction during pregnancy complicated by antiphospholipid syndrome. ( Kinoshita, K, 1993) |
| "Thrombotic thrombocytopenic purpura is a severe multisystemic disorder of unknown origin." | 1.28 | Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura. ( Eldor, A; Ezra, Y; Mordel, N; Sadovsky, E; Schenker, JG, 1989) |
| "After treatment the pregnancy wastage rate was 55% and 25% in the 2 groups respectively." | 1.28 | Pregnancy loss with phospholipid antibodies: improved outcome with aspirin containing treatment. ( Cameron, K; Gatenby, PA; Shearman, RP, 1989) |
| "A clinical diagnosis of systemic lupus erythematosus (SLE) was made in four women." | 1.27 | Lupus anticoagulant in pregnancy. ( Butler, WS; Liggins, GC; Lubbe, WF; Palmer, SJ, 1984) |
| "Beagle bitches were administered aspirin at either 100 or 400 mg/kg/day between Days 15 and 22 or Days 23 and 30 postmating, and corresponding control groups were dosed with vehicle during one of these same time periods." | 1.26 | Aspirin: teratogenic evaluation in the dog. ( Allen, HL; Bokelman, DL; Robertson, RT, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (32.77) | 18.7374 |
| 1990's | 37 (31.09) | 18.2507 |
| 2000's | 28 (23.53) | 29.6817 |
| 2010's | 13 (10.92) | 24.3611 |
| 2020's | 2 (1.68) | 2.80 |
| Authors | Studies |
|---|---|
| Cardoso, MIMP | 1 |
| Rezende, KBC | 1 |
| Da Matta, FG | 1 |
| Saunders, C | 1 |
| Cardoso, FFO | 1 |
| Costa Junior, IB | 1 |
| Gama, LB | 1 |
| Amim, J | 1 |
| Bornia, RG | 1 |
| Gangat, N | 1 |
| Guglielmelli, P | 1 |
| Al-Kali, A | 1 |
| Wolanskyj-Spinner, AP | 1 |
| Camoriano, J | 1 |
| Patnaik, MM | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Vannucchi, AM | 1 |
| Tefferi, A | 2 |
| Schreiber, K | 1 |
| Radin, M | 1 |
| Sciascia, S | 1 |
| Belhomme, N | 1 |
| Doudnikoff, C | 1 |
| Polard, E | 1 |
| Henriot, B | 1 |
| Isly, H | 1 |
| Jego, P | 1 |
| Navaratnam, K | 1 |
| Alfirevic, A | 1 |
| Jorgensen, A | 1 |
| Alfirevic, Z | 1 |
| Khazardoost, S | 1 |
| Mousavi, S | 1 |
| Borna, S | 1 |
| Hantoushzadeh, S | 1 |
| Alavi, A | 1 |
| Khezerlou, N | 1 |
| Mekinian, A | 2 |
| Costedoat-Chalumeau, N | 1 |
| Masseau, A | 1 |
| Botta, A | 1 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| Hachulla, E | 2 |
| De Carolis, S | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 2 |
| Carbillon, L | 2 |
| Fain, O | 2 |
| Mutlu, I | 1 |
| Mutlu, MF | 1 |
| Biri, A | 1 |
| Bulut, B | 1 |
| Erdem, M | 1 |
| Erdem, A | 1 |
| Terada, K | 1 |
| Nakanishi, K | 1 |
| Suzuki, S | 1 |
| Abheiden, CN | 1 |
| van Reuler, AV | 1 |
| Fuijkschot, WW | 1 |
| de Vries, JI | 1 |
| Thijs, A | 1 |
| de Boer, MA | 1 |
| Le Guern, V | 1 |
| Goffinet, F | 1 |
| Ruiz-Irastorza, G | 2 |
| Martinez-Berriotxoa, A | 1 |
| Egurbide, MV | 1 |
| Ogishima, H | 1 |
| Ito, S | 1 |
| Tsutsumi, A | 1 |
| Sugihara, M | 1 |
| Goto, D | 1 |
| Matsumoto, I | 1 |
| Obata-Yasuoka, M | 1 |
| Hamada, H | 1 |
| Yoshikawa, H | 1 |
| Takahashi, H | 1 |
| Murashima, A | 1 |
| Sumida, T | 1 |
| Khamashta, MA | 1 |
| Loire-Berson, P | 1 |
| Nicaise-Roland, P | 1 |
| Lachassinne, E | 1 |
| Stirnemann, J | 1 |
| Boffa, MC | 1 |
| Roberge, S | 1 |
| Nicolaides, KH | 1 |
| Demers, S | 1 |
| Villa, P | 1 |
| Bujold, E | 1 |
| Becker, R | 1 |
| Keller, T | 1 |
| Kiesewetter, H | 1 |
| Fangerau, H | 1 |
| Bittner, U | 1 |
| Biasiutti, FD | 1 |
| Strebel, JK | 1 |
| Kozer, E | 1 |
| Costei, AM | 1 |
| Boskovic, R | 1 |
| Nulman, I | 1 |
| Nikfar, S | 1 |
| Koren, G | 1 |
| EARLEY, PA | 1 |
| HAYDEN, J | 1 |
| Abraitis, V | 1 |
| Mongirdiene, A | 1 |
| Mockeviciene, A | 1 |
| Gris, JC | 1 |
| Mercier, E | 1 |
| Quéré, I | 1 |
| Lavigne-Lissalde, G | 1 |
| Cochery-Nouvellon, E | 1 |
| Hoffet, M | 1 |
| Ripart-Neveu, S | 1 |
| Tailland, ML | 1 |
| Dauzat, M | 1 |
| Marès, P | 1 |
| Bats, AS | 1 |
| Lejeune, V | 1 |
| Cynober, E | 1 |
| Safar, E | 1 |
| Gonzales, M | 1 |
| Milliez, J | 1 |
| Carbonne, B | 1 |
| Gromnica-Ihle, E | 1 |
| Wisløff, F | 1 |
| Crowther, M | 1 |
| Niittyvuopio, R | 1 |
| Juvonen, E | 1 |
| Kaaja, R | 2 |
| Oksanen, K | 1 |
| Hallman, H | 1 |
| Timonen, T | 1 |
| Ruutu, T | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Alijotas-Reig, J | 1 |
| San Miguel-Moncín, M | 1 |
| Cisteró-Bahíma, A | 1 |
| Mégarbane, B | 1 |
| Baud, F | 1 |
| Kornacka, MK | 1 |
| Bokiniec, R | 1 |
| Duley, L | 3 |
| Henderson-Smart, DJ | 1 |
| Meher, S | 1 |
| King, JF | 1 |
| Hossain, N | 1 |
| Paidas, MJ | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Rey, E | 1 |
| David, M | 1 |
| Chandiramani, M | 1 |
| Seed, P | 1 |
| Poston, L | 1 |
| Shennan, AH | 1 |
| Lubbe, WF | 3 |
| Butler, WS | 2 |
| Palmer, SJ | 2 |
| Liggins, GC | 3 |
| Niederhoff, H | 1 |
| Zahradnik, HP | 1 |
| Grabowski, CT | 1 |
| Vandekerckhove, F | 1 |
| Noens, L | 1 |
| Colardyn, F | 1 |
| Thiery, M | 1 |
| Delbarge, W | 1 |
| Goodlin, RC | 1 |
| Machlin, LJ | 1 |
| Gabriel, E | 1 |
| Horn, LR | 1 |
| Woo, D | 1 |
| Filipski, R | 1 |
| Brin, M | 1 |
| Nelson, J | 1 |
| Dror, Y | 1 |
| Gelman-Kohan, Z | 1 |
| Hagai, Z | 1 |
| Juster-Reicher, A | 1 |
| Cohen, RN | 1 |
| Mogilner, B | 1 |
| Zahner, J | 1 |
| Wehmeier, A | 1 |
| Schneider, W | 1 |
| Moya, FR | 1 |
| Germain, A | 1 |
| Kinoshita, K | 1 |
| Stuart, RA | 1 |
| Quinn, MJ | 1 |
| McHugh, NJ | 1 |
| Rogov, VA | 1 |
| Tareeva, IE | 1 |
| Sidorova, IS | 1 |
| Androsova, SO | 1 |
| Katamadze, KT | 1 |
| Nikiforova, OV | 1 |
| Carp, HJ | 1 |
| Menashe, Y | 1 |
| Frenkel, Y | 1 |
| Many, A | 1 |
| Nebel, L | 1 |
| Toder, V | 1 |
| Mashiach, S | 1 |
| Cusick, W | 1 |
| Salafia, CM | 1 |
| Ernst, L | 1 |
| Rodis, JF | 1 |
| Campbell, WA | 1 |
| Vintzileos, AM | 1 |
| Ezra, Y | 2 |
| Rose, M | 1 |
| Eldor, A | 2 |
| McCowan, LM | 1 |
| Buist, RG | 1 |
| North, RA | 1 |
| Gamble, G | 1 |
| Cowchock, S | 1 |
| Griesshammer, M | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Mazzucconi, MG | 1 |
| Dragoni, F | 1 |
| Chistolini, A | 1 |
| Peraino, M | 1 |
| Paesano, R | 1 |
| Di Prima, M | 1 |
| Di Francesco, F | 1 |
| Masala, C | 1 |
| Pachì, A | 1 |
| Reece, EA | 1 |
| Garofalo, J | 1 |
| Zheng, XZ | 1 |
| Assimakopoulos, E | 1 |
| González Campos, J | 1 |
| Monedero, M | 1 |
| Vinuesa, M | 1 |
| Alvarez, D | 1 |
| Digón, J | 1 |
| Rodríguez, JM | 1 |
| Palatnick, W | 1 |
| Tenenbein, M | 1 |
| Rojas-Poceros, G | 1 |
| Ramírez Peredo, J | 1 |
| Hernández Andrade, E | 1 |
| Bustos López, HH | 1 |
| Rotchell, YE | 1 |
| Cruickshank, JK | 1 |
| Gay, MP | 1 |
| Griffiths, J | 1 |
| Stewart, A | 1 |
| Farrell, B | 1 |
| Ayers, S | 1 |
| Hennis, A | 1 |
| Grant, A | 1 |
| Collins, R | 1 |
| Cyrkowicz, A | 1 |
| Przybycień, J | 1 |
| Sullivan, MH | 1 |
| Clark, NA | 1 |
| de Swiet, M | 1 |
| Nelson-Piercy, C | 1 |
| Elder, MG | 1 |
| Oyelese, KO | 1 |
| Black, RS | 1 |
| Lees, CC | 1 |
| Campbell, S | 1 |
| Costa, M | 1 |
| Rossi, E | 1 |
| Julkunen, H | 1 |
| Jouhikainen, T | 1 |
| Piette, AM | 1 |
| Hatron, PY | 1 |
| Blétry, O | 1 |
| Kaburaki, J | 1 |
| Kuwana, M | 1 |
| Henderson-Smart, D | 1 |
| Knight, M | 1 |
| King, J | 1 |
| Soregaroli, M | 1 |
| Valcamonico, A | 1 |
| Scalvi, L | 1 |
| Danti, L | 1 |
| Frusca, T | 1 |
| Wright, CA | 1 |
| Vials, JM | 1 |
| Erkan, D | 1 |
| Merrill, JT | 1 |
| Yazici, Y | 1 |
| Sammaritano, L | 1 |
| Buyon, JP | 1 |
| Lockshin, MD | 2 |
| Maharaj, R | 1 |
| Vantroyen, B | 1 |
| Vanstraelen, D | 1 |
| Koh, LP | 1 |
| Devendra, K | 1 |
| Tien, SL | 1 |
| Shapiro, S | 1 |
| Siskind, V | 1 |
| Monson, RR | 1 |
| Heinonen, OP | 1 |
| Kaufman, DW | 1 |
| Slone, D | 1 |
| Collins, E | 1 |
| Turner, G | 1 |
| Karim, SM | 1 |
| Corby, DG | 1 |
| Wilson, JG | 2 |
| Ritter, EJ | 1 |
| Scott, WJ | 1 |
| Fradkin, R | 1 |
| Robertson, RT | 1 |
| Allen, HL | 1 |
| Bokelman, DL | 1 |
| Woo, DC | 1 |
| McClain, RM | 1 |
| Hoar, RM | 1 |
| O'Dell, BL | 1 |
| Reynolds, G | 1 |
| Reeves, PG | 1 |
| Fritz, H | 1 |
| Tuchmann-Duplessis, H | 1 |
| Hiss, D | 1 |
| Mottot, G | 1 |
| Rosner, I | 1 |
| Faivre, J | 1 |
| Faivre, M | 1 |
| Lery, N | 1 |
| Mukherjee, AB | 1 |
| Chan, M | 1 |
| Waite, R | 1 |
| Metzger, MI | 1 |
| Yaffee, SJ | 1 |
| Passaleva, A | 1 |
| Massai, G | 1 |
| D'Elios, MM | 1 |
| Livi, C | 1 |
| Abbate, R | 1 |
| Sedano, M | 1 |
| Palma, S | 1 |
| González, P | 1 |
| Neira, O | 1 |
| Abumohor, P | 1 |
| Cerda, C | 1 |
| Guzmán, L | 1 |
| Takashima, M | 1 |
| Yamasaki, M | 1 |
| Ohashi, M | 1 |
| Morikawa, H | 1 |
| Mochizuki, M | 1 |
| Font, J | 1 |
| López-Soto, A | 1 |
| Cervera, R | 1 |
| Balasch, J | 1 |
| Pallarés, L | 1 |
| Navarro, M | 1 |
| Bosch, X | 1 |
| Ingelmo, M | 1 |
| Sureau, C | 1 |
| Wise, LD | 1 |
| Vetter, CM | 1 |
| Anderson, CA | 1 |
| Antonello, JM | 1 |
| Clark, RL | 1 |
| Randall, CL | 1 |
| Anton, RF | 1 |
| Becker, HC | 1 |
| Hale, RL | 1 |
| Ekblad, U | 1 |
| Branch, DW | 2 |
| Pineo, GF | 1 |
| Blahey, WB | 1 |
| Keirse, MJ | 1 |
| Shimmyozu, K | 1 |
| Okadome, T | 1 |
| Maruyama, Y | 1 |
| Maruyama, I | 1 |
| Osame, M | 1 |
| Tara, M | 1 |
| Gendron, RL | 1 |
| Farookhi, R | 1 |
| Baines, MG | 1 |
| Mordel, N | 1 |
| Sadovsky, E | 1 |
| Schenker, JG | 1 |
| Gatenby, PA | 1 |
| Cameron, K | 1 |
| Shearman, RP | 1 |
| Wallenburg, HC | 1 |
| Rotmans, N | 1 |
| Druzin, ML | 1 |
| Qamar, T | 1 |
| Scott, JR | 1 |
| Kochenour, NK | 1 |
| Hershgold, E | 1 |
| Rejent, TA | 1 |
| Baik, S | 1 |
| Courtney, KD | 1 |
| Valerio, DA | 1 |
| Eriksson, M | 2 |
| MacDonald, PC | 1 |
| Schultz, FM | 1 |
| Duenhoelter, JH | 1 |
| Gant, NF | 1 |
| Jimenez, JM | 1 |
| Pritchard, JA | 1 |
| Porter, JC | 1 |
| Johnston, JM | 1 |
| Kriegel, H | 1 |
| Waltman, R | 1 |
| Tricomi, V | 1 |
| Shabanah, EH | 1 |
| Arenas, R | 1 |
| Aiken, JW | 1 |
| Chester, R | 1 |
| Dukes, M | 1 |
| Slater, SR | 1 |
| Walpole, AL | 1 |
| Jewett, JF | 1 |
| Crombie, DL | 1 |
| Pinsent, RJ | 1 |
| Slater, BC | 1 |
| Fleming, D | 1 |
| Cross, KW | 1 |
| Kimmel, CA | 1 |
| Schumacher, HJ | 1 |
| Pap, AG | 1 |
| Tarakhovskiĭ, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population[NCT05089175] | 4,500 participants (Anticipated) | Observational [Patient Registry] | 2021-11-30 | Recruiting | |||
| A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573] | Phase 3 | 400 participants (Anticipated) | Interventional | 2019-10-21 | Enrolling by invitation | ||
| Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome[NCT04275778] | Phase 2 | 110 participants (Anticipated) | Interventional | 2021-07-09 | Recruiting | ||
| Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol[NCT05709483] | Early Phase 1 | 130 participants (Anticipated) | Interventional | 2023-04-13 | Recruiting | ||
| Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.[NCT02797249] | Phase 3 | 1,000 participants (Actual) | Interventional | 2016-12-07 | Completed | ||
| PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy[NCT06115122] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2022-02-15 | Recruiting | |||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial[NCT02754635] | 320 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | |||
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)[NCT03152058] | Phase 2 | 55 participants (Anticipated) | Interventional | 2017-05-17 | Recruiting | ||
| Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls[NCT03151330] | 2,110 participants (Anticipated) | Interventional | 2018-06-15 | Active, not recruiting | |||
| A Study of the Pharmacology of 17-Hydroxyprogesterone Caproate in Pregnancy[NCT00409825] | Phase 2 | 61 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
"Change in the area under the concentration vs. time curve in the second and third trimesters of pregnancy.~We compared AUC at each PK study visit. Measurements were obtained at 0, 1, 2, 3, 4, 5, 6, 7 days." (NCT00409825)
Timeframe: Second and third trimesters of pregnancy
| Intervention | ng/ML/day (Mean) | |
|---|---|---|
| AUC -1 | AUC - 2 | |
| Part 1 | 115 | 136 |
36 reviews available for aspirin and Fetal Death
| Article | Year |
|---|---|
Current insights in obstetric antiphospholipid syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2017 |
[Aspirin: Indications and use during pregnancy].
Topics: Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pregnancy, | 2017 |
[Pregnancy and antiphospholipid antibodies].
Topics: Animals; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Complemen | 2008 |
[The antiphospholipid syndrome in the 21st century].
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri | 2009 |
Lupus and pregnancy: integrating clues from the bench and bedside.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli | 2011 |
Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.
Topics: Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Perinatal Mortality; Platelet Aggreg | 2013 |
[Anticoagulation and antiaggregation during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abruptio Placentae; Administration, Oral; Adult; | 2003 |
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis.
Topics: Abnormalities, Drug-Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; | 2003 |
[Factor V Leiden mutation and pregnancy complications].
Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem | 2003 |
Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy.
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Arteries; Aspirin; Female; Fetal Deat | 2004 |
Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Ev | 2004 |
Pregnancy in essential thrombocythaemia: experience with 40 pregnancies.
Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Eclampsia; Female; Fetal Death; Finland; Humans; Pla | 2004 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
[Acute poisoning: general management and main causes].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Alcoholic Intoxication; Amphetamines; Analgesics; | 2006 |
[Newborn from mother with antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Female; Fet | 2006 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Fetal Death; Humans; Obstetric Labor, Premature; Platelet Aggregation Inhibitors; P | 2007 |
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.
Topics: Anticoagulants; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Heparin; Humans; Immunoglobu | 2007 |
Analgesics during pregnancy.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; Female; Fetal Death; | 1983 |
The electrocardiogram of fetal and newborn rats and dysrhythmias induced by toxic exposure.
Topics: Animals; Animals, Newborn; Arrhythmias, Cardiac; Aspirin; Dose-Response Relationship, Drug; Electroc | 1983 |
[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child].
Topics: Abortion, Spontaneous; Adult; Aspirin; Female; Fetal Death; Growth Disorders; Humans; Infant, Newbor | 1995 |
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Combined Modality Therapy; Diagnostic Errors; Dipyridamole; | 1996 |
Prevention of fetal death in the antiphospholipid antibody syndrome.
Topics: Adrenal Cortex Hormones; Animals; Antiphospholipid Syndrome; Aspirin; Female; Fetal Death; Heparin; | 1996 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
[Intra-uterine fetal death syndrome--not only a gynecologic problem].
Topics: Adrenocorticotropic Hormone; Aspirin; Blood Coagulation Disorders; Female; Fetal Death; Heparin; Hum | 1997 |
[Phospholipid antigens, thrombosis and repeated fetal death].
Topics: Abortion, Habitual; Adult; Antigens; Aspirin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; | 1996 |
[Aspirin and antiphospholipid syndrome].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc | 2000 |
[Diagnosis and management for antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female | 2000 |
Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review.
Topics: Aspirin; Female; Fetal Death; Humans; Infant, Newborn; Obstetric Labor, Premature; Platelet Aggregat | 2001 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
A literature review on the antiphospholipid syndrome and the effect on childbearing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F | 2001 |
Do acetylsalicylic acid and other antiplatelet drugs prevent preeclampsia?
Topics: Aspirin; Autoimmune Diseases; Clinical Trials as Topic; Diabetes Complications; Dose-Response Relati | 2001 |
Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature.
Topics: Abortion, Spontaneous; Aspirin; Blood Component Removal; Female; Fetal Death; Gestational Age; Human | 2002 |
On the use of blockers of prostaglandin synthesis in the control of labor.
Topics: Animals; Aspirin; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Indome | 1978 |
Aspirin in pregnancy: maternal and fetal effects.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Birth Weight; Cleft Lip; Cleft Palate; Female; Fetal | 1978 |
Antiphospholipid syndrome: laboratory concerns, fetal loss, and pregnancy management.
Topics: Adrenal Cortex Hormones; Aspirin; Autoimmune Diseases; Female; Fetal Death; Heparin; Humans; Phospho | 1991 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
10 trials available for aspirin and Fetal Death
| Article | Year |
|---|---|
Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein.
Topics: Adult; alpha-Fetoproteins; Aspirin; Female; Fetal Death; Humans; Pre-Eclampsia; Pregnancy; Pregnancy | 2014 |
Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.
Topics: Aspirin; Birth Weight; Enoxaparin; Female; Fetal Death; Folic Acid; Heparin, Low-Molecular-Weight; H | 2004 |
Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Desensitization, Immunologic; Female; Fetal Death; Follow | 2006 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Humans; Infant Mortalit | 1994 |
[Acetylsalicylic acid and kurantil in the prevention of pregnancy complications in glomerulonephritis and hypertension].
Topics: Abortion, Spontaneous; Analysis of Variance; Aspirin; Chronic Disease; Dipyridamole; Drug Therapy, C | 1993 |
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group.
Topics: Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; Follow-Up Studies; Humans; Obs | 1996 |
Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.
Topics: Adult; Aspirin; Barbados; Birth Weight; Delayed-Action Preparations; Female; Fetal Death; Gestationa | 1998 |
Antiphospholipid antibodies and pregnancy.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Birth Rate; Female; Fetal | 1999 |
On the use of blockers of prostaglandin synthesis in the control of labor.
Topics: Animals; Aspirin; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Indome | 1978 |
Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group.
Topics: Abruptio Placentae; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Combinations; Fem | 1991 |
74 other studies available for aspirin and Fetal Death
| Article | Year |
|---|---|
The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin.
Topics: Aspirin; Brazil; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans; Infant, New | 2023 |
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Diabetes, Gestational; Female; Fetal Death; Hemo | 2021 |
Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia.
Topics: Adult; Aspirin; Female; Fetal Death; Humans; Middle Aged; Platelet Aggregation Inhibitors; Pre-Eclam | 2018 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D | 2015 |
Clinical characteristics of pregnancies with a history of recurrent miscarriage at a Japanese perinatal center.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Case-Control Studies; Cesarean Section; Female; | 2015 |
Aspirin adherence during high-risk pregnancies, a questionnaire study.
Topics: Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Health Knowledge, Attitudes, Practice | 2016 |
High-dose unfractionated heparin therapy in a pregnant patient with antiphospolipid syndrome: a case report.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation; Cesarean Section; Drug Monito | 2010 |
Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Comorbi | 2012 |
Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.
Topics: Algorithms; Anticoagulants; Aspirin; Body Mass Index; Female; Fetal Death; Fetal Growth Retardation; | 2013 |
EFFECT OF ACETYLSALICYLIC ACID ON FOETAL RABBITS.
Topics: Abnormalities, Drug-Induced; Aspirin; Female; Fetal Death; Fetus; Humans; Maternal-Fetal Exchange; P | 1964 |
[Which abortion prevention should be chosen in the case of antiphospholipid syndrome?].
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Adult; Anticoagulants; Antiphospholipid Syndrome; As | 2004 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
Antiplatelet agents for prevention of pre-eclampsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Fetal Death; Humans; Infant Mortality; Inf | 2007 |
Fetal survival after prednisone suppression of maternal lupus-anticoagulant.
Topics: Adult; Antibodies, Antinuclear; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Fem | 1983 |
Lupus anticoagulant in pregnancy.
Topics: Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Chorea; Drug Therapy, Combination; | 1984 |
Thrombotic thrombocytopenic purpura mimicking toxemia of pregnancy.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Diagnosis, Differential; Dipyridamole; Female; Fetal Death; | 1984 |
Correction of pregnancy-related thrombocytopenia with aspirin without improvement in fetal outcome.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Fetal Death; Fetal Growth Retardation; Humans; Pl | 1983 |
Effects of aspirin and related drugs in vitamin E-deficient rats.
Topics: Animals; Aspirin; Blood Cell Count; Female; Fetal Death; Hematocrit; Hemoglobins; Hemolysis; Male; P | 1980 |
Aplasia cutis congenita, elevated alpha-fetoprotein, and a distinct amniotic fluid acetylcholinesterase electrophoretic band.
Topics: Acetylcholinesterase; Adult; alpha-Fetoproteins; Amniotic Fluid; Aspirin; Diseases in Twins; Ectoder | 1994 |
Prevention of preeclampsia with low-dose aspirin.
Topics: Aspirin; Chi-Square Distribution; Female; Fetal Death; Humans; Pre-Eclampsia; Pregnancy | 1994 |
Hepatic infarction during pregnancy complicated by antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Female; Fetal Death; Humans; Infarction; Liver; Prednisol | 1993 |
Combined corticosteroid and aspirin treatment for the high risk lupus pregnancy.
Topics: Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Gestational Age; | 1993 |
Lupus anticoagulant. Significance in habitual first-trimester abortion.
Topics: Abortion, Habitual; Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Lupus Coa | 1993 |
Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes.
Topics: Adolescent; Adult; Aspirin; Drug Administration Schedule; Eclampsia; Female; Fetal Death; Humans; Pl | 1995 |
Perinatal morbidity in chronic hypertension.
Topics: Adult; Aspirin; Chronic Disease; Cohort Studies; Female; Fetal Death; Humans; Hypertension; Infant M | 1996 |
Efficacy of low dose prednisone plus aspirin in preventing spontaneous abortions and/or fetal deaths due to antiphospholipid antibodies: results of a pilot study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Aspirin; Drug Administration Schedule; D | 1996 |
Pregnancy outcome. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Fema | 1997 |
[Abortions caused by anticardiolipin antibodies: prevention by low-dose acetylsalicylic acid].
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Autoimmu | 1997 |
Aspirin poisoning during pregnancy: increased fetal sensitivity.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Gas Analysis; Blood Glucose; Diu | 1998 |
[Recurrent fetal death and antiphospholipid antibody syndrome. A case report].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; | 1997 |
Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
Topics: Abortion, Spontaneous; Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; | 1998 |
A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Fetal Growth Retardation; Fetal Moni | 1998 |
Late normalisation of uterine artery velocimetry in high risk pregnancy.
Topics: Arteries; Aspirin; Blood Flow Velocity; Dose-Response Relationship, Drug; Female; Fetal Death; Human | 2001 |
High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Heparin; | 2001 |
Four pregnancies in two patients with essential thrombocythaemia--a case report.
Topics: Adult; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Female; Fetal Death; Humans; H | 2002 |
Perinatal mortality and birth-weight in relation to aspirin taken during pregnancy.
Topics: Aspirin; Birth Weight; Black People; Female; Fetal Death; Humans; Infant, Newborn; Infant, Newborn, | 1976 |
Aspirin during pregnancy.
Topics: Aspirin; Female; Fetal Death; Fetus; Humans; Pregnancy | 1976 |
Comparative distribution and embryotoxicity of acetylsalicylic acid in pregnant rats and rhesus monkeys.
Topics: Animals; Aspirin; Embryo, Mammalian; Female; Fetal Death; Fetal Resorption; Haplorhini; Macaca mulat | 1977 |
Aspirin: teratogenic evaluation in the dog.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Dogs; Dose-Response Relationship, Drug; Female; Fetal | 1979 |
Potentiation of methotrexate embryolethality by aspirin in rats.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Body Weight; Drug Synergism; Embryo, Mammalian; Femal | 1978 |
Analogous effects of zinc deficiency and aspirin toxicity in the pregnant rat.
Topics: Aldosterone; Animals; Aspirin; Blood Coagulation; Calcium; Female; Fetal Death; Potassium; Pregnancy | 1977 |
The effect of cortisone on the teratogenic action of acetylsalicylic acid and diphenylhydantoin in the mouse.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cleft Palate; Cortisone; Drug Administration Schedule | 1976 |
Effects of prenatal administration of acetylsalicylic acid in rats.
Topics: Animals; Animals, Newborn; Aspirin; Behavior, Animal; Body Weight; Female; Fetal Death; Pregnancy; P | 1975 |
[Aspirin and pregnancy].
Topics: Animals; Aspirin; Female; Fetal Death; Fetus; Humans; Pregnancy; Pregnancy Trimester, First; Pregnan | 1975 |
Inhibition of RNA synthesis by acetyl salicylate and actinomycin D during early development in the mouse.
Topics: Animals; Aspirin; Autoradiography; Breeding; Dactinomycin; Depression, Chemical; Female; Fetal Death | 1975 |
Prevention of miscarriage in antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Female; | 1992 |
[Recurrent loss of pregnancy in patients with anticardiolipin antibodies (ACAb)].
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Aspirin; Drug Therapy, Combination; Female; | 1992 |
[A trial of low-dose aspirin therapy in high-risk pregnancy].
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Calcium; Female; Fetal Death; Fetal Growth Retardation; Human | 1992 |
The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin | 1991 |
Reversible effects of triamcinolone and lack of effects with aspirin or L-656,224 on external genitalia of male Sprague-Dawley rats exposed in utero.
Topics: Abnormalities, Drug-Induced; Animals; Arachidonic Acid; Aspirin; Benzofurans; Female; Fetal Death; G | 1991 |
Aspirin dose-dependently reduces alcohol-induced birth defects and prostaglandin E levels in mice.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Dose-Response Relationship, Drug; Ethanol; Female; Fe | 1991 |
Essential thrombocythemia and complications of pregnancy.
Topics: Abortion, Incomplete; Aspirin; Female; Fetal Death; Humans; Pregnancy; Pregnancy Complications, Hema | 1991 |
[Aspirin and pregnancy].
Topics: Aspirin; Blood Coagulation Factors; Female; Fetal Death; Fetal Growth Retardation; Humans; Hypertens | 1990 |
[Fetal survival after the corticosteroid and low-dose aspirin regimen in a case of anti-phospholipid antibody syndrome].
Topics: Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Drug Therapy, Combination; Female; Fetal Death; | 1990 |
Resorption of CBA/J x DBA/2 mouse conceptuses in CBA/J uteri correlates with failure of the feto-placental unit to suppress natural killer cell activity.
Topics: Animals; Aspirin; Female; Fetal Death; Fetal Resorption; Fetus; Gestational Age; Killer Cells, Natur | 1990 |
Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura.
Topics: Adult; Aspirin; Blood Transfusion; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combinatio | 1989 |
Pregnancy loss with phospholipid antibodies: improved outcome with aspirin containing treatment.
Topics: Abortion, Spontaneous; Antibodies; Aspirin; Female; Fetal Death; Humans; Lupus Erythematosus, System | 1989 |
Prophylactic low-dose aspirin and dipyridamole in pregnancy.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Fetal Death; Fetal Growth Retardation; Hum | 1988 |
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.
Topics: Aspirin; Autoantibodies; Female; Fetal Death; Humans; Lupus Erythematosus, Systemic; Phospholipids; | 1989 |
Obstetric complications associated with the lupus anticoagulant.
Topics: Abortion, Spontaneous; Aspirin; Blood Coagulation Factors; Blood Coagulation Tests; Female; Fetal De | 1985 |
Fatal in utero salicylism.
Topics: Aspirin; Female; Fetal Death; Gestational Age; Humans; Maternal-Fetal Exchange; Pregnancy; Suicide, | 1985 |
Teratology in the Macaca mulatta.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Clomiphene; Encephalocele; Female; Fetal Death; Haplo | 1968 |
Salicylate-induced foetal damage late in pregnancy. An experimental study in mice.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Aspirin; Carbon Isotopes; Coumarins; Female; | 1971 |
Initiation of human parturition. I. Mechanism of action of arachidonic acid.
Topics: Abortifacient Agents; Abortion, Induced; Amniotic Fluid; Animals; Arachidonic Acids; Aspirin; Dogs; | 1974 |
[Effect of an acetylsalicylic acid-quinidine-lithium-combination on the fertility of mice].
Topics: Administration, Oral; Animals; Animals, Newborn; Aspirin; Drug Combinations; Embryo, Mammalian; Fema | 1974 |
The effect of anti-inflammatory drugs on parturition parameters in the rat.
Topics: Acetates; Animals; Aspirin; Cortisone; Depression, Chemical; Female; Fetal Death; Gestational Age; L | 1973 |
Aspirin and indomethacin prolong parturition in rats: evidence that prostaglandins contribute to expulsion of fetus.
Topics: Administration, Oral; Animals; Aspirin; Biological Assay; Chickens; Chromatography, Thin Layer; Fema | 1972 |
Delay of parturition in the rat by anti-inflammatory agents which inhibit the biosynthesis of prostaglandins.
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Cortisone; Depression, C | 1972 |
Salicylate poisoning.
Topics: Adult; Aspirin; Female; Fetal Death; Humans; Poisoning; Pregnancy; Pregnancy Complications; Salicyla | 1973 |
Salicylate-induced foetal damage during late pregnancy in mice: a comparison between sodium salicylate, acetylsalicylic acid and salicylsalicylic acid.
Topics: Animals; Aspirin; Female; Fetal Death; Gestational Age; Hemorrhage; Liver Glycogen; Mice; Pregnancy; | 1971 |
Teratogenic drugs--R.C.G.P. survey.
Topics: Abnormalities, Drug-Induced; Aspirin; Barbiturates; Female; Fetal Death; Hormones; Humans; Iron; Pre | 1970 |
Studies on metabolism and identification of the causative agent in aspirin teratogenesis in rats.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Benzoates; Biotransformation; Female; Fetal Death; Fe | 1971 |
[Effect of several drugs on the fetus].
Topics: Abnormalities, Drug-Induced; Aminopyrine; Animals; Aspirin; Benzimidazoles; Chlorpromazine; Cortison | 1967 |